Apollon Wealth Management LLC Buys 8,209 Shares of AbbVie Inc. (NYSE:ABBV)

Apollon Wealth Management LLC increased its position in AbbVie Inc. (NYSE:ABBV) by 11.6% during the 4th quarter, Holdings Channel reports. The firm owned 79,230 shares of the company’s stock after acquiring an additional 8,209 shares during the quarter. Apollon Wealth Management LLC’s holdings in AbbVie were worth $14,079,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Opinicus Capital Inc. grew its position in shares of AbbVie by 5.2% during the 4th quarter. Opinicus Capital Inc. now owns 9,217 shares of the company’s stock worth $1,638,000 after buying an additional 458 shares in the last quarter. TFG Advisers LLC raised its holdings in shares of AbbVie by 0.5% in the fourth quarter. TFG Advisers LLC now owns 20,830 shares of the company’s stock valued at $3,702,000 after acquiring an additional 111 shares in the last quarter. MWA Asset Management lifted its stake in AbbVie by 1.4% in the fourth quarter. MWA Asset Management now owns 16,805 shares of the company’s stock worth $2,986,000 after acquiring an additional 229 shares during the period. Vest Financial LLC grew its holdings in AbbVie by 7.9% during the 4th quarter. Vest Financial LLC now owns 308,782 shares of the company’s stock worth $54,871,000 after acquiring an additional 22,502 shares in the last quarter. Finally, Cidel Asset Management Inc. increased its position in AbbVie by 3.1% during the 4th quarter. Cidel Asset Management Inc. now owns 7,194 shares of the company’s stock valued at $1,278,000 after purchasing an additional 213 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Trading Down 1.2 %

Shares of AbbVie stock opened at $190.67 on Friday. The stock has a market cap of $336.94 billion, a PE ratio of 79.45, a price-to-earnings-growth ratio of 1.84 and a beta of 0.58. The firm has a fifty day moving average price of $177.38 and a 200 day moving average price of $185.48. AbbVie Inc. has a 1 year low of $153.58 and a 1 year high of $207.32. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 257.91%. During the same period last year, the firm posted $2.79 earnings per share. Equities research analysts predict that AbbVie Inc. will post 12.26 earnings per share for the current year.

Insider Transactions at AbbVie

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the sale, the senior vice president now directly owns 6,983 shares of the company’s stock, valued at approximately $1,202,751.92. This represents a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ABBV shares. UBS Group increased their price objective on shares of AbbVie from $181.00 to $190.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Wolfe Research started coverage on AbbVie in a research report on Friday, November 15th. They set an “outperform” rating and a $205.00 target price on the stock. Citigroup boosted their price target on AbbVie from $205.00 to $215.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Truist Financial lifted their target price on AbbVie from $211.00 to $217.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Finally, Daiwa Capital Markets lowered shares of AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 price target for the company. in a research report on Thursday, December 5th. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $208.35.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.